Impact of ERCC1 on the outcomes of chemotherapy in advanced biliary tract cancer

Abstract The phase III randomized trial, JCOG1113 has demonstrated the non-inferiority of gemcitabine and S-1 (GS) therapy to gemcitabine and cisplatin (GC) therapy for advanced biliary tract cancer (BTC). However, biomarkers for favorable therapy or to predict patient prognosis remain lacking. In t...

Full description

Bibliographic Details

Published in:	Scientific Reports
Main Authors:	Yasunari Sakamoto, Chigusa Morizane, Takuji Okusaka, Junki Mizusawa, Nobuyoshi Hiraoka, Tomoki Shirota, Makoto Ueno, Satoshi Kobayashi, Masafumi Ikeda, Hiroshi Imaoka, Masato Ozaka, Naohiro Okano, Hironori Yamaguchi, Nobumasa Mizuno, Tomohiro Nishina, Akio Katanuma, Yasushi Kojima, Kunihito Gotoh, Keiya Okamura, Yasuyuki Kawamoto, Kazuya Sugimori, Takeshi Terashima, Rie Sugimoto, Hirofumi Shirakawa, Junji Furuse
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-09-01
Subjects:	ERCC1 Biliary tract cancer Chemotherapy Prognostic factor
Online Access:	https://doi.org/10.1038/s41598-025-07058-7